Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial

INTRODUCTION: Older adults are subject to higher COVID-19 infection and mortality rates. Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated in phase 2 clinical trial for the general population, and negative correlations have been observed between immune respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Waits, Alexander, Chen, Jau-Yuan, Cheng, Wei-Hong, Yeh, Jih-I, Hsieh, Szu-Min, Chen, Charles, Janssen, Robert, Lien, Chia En, Lin, Tzou-Yien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422336/
https://www.ncbi.nlm.nih.gov/pubmed/36049700
http://dx.doi.org/10.1016/j.ijid.2022.08.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422336/
https://www.ncbi.nlm.nih.gov/pubmed/36049700
http://dx.doi.org/10.1016/j.ijid.2022.08.021

Ejemplares similares